The therapeutic application of Bi-Profenid LP (Ketoprofen prolonged-release) may be part of symptomatic management for conditions involving inflammatory or irritative states. It is generally used across multiple therapeutic domains characterized by heightened symptoms of pain and swelling.

This medication is used for managing conditions, including Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, Primary Dysmenorrhea, and acute episodes following sprains or contusions. It addresses the discomfort of these conditions by providing systemic symptomatic support. The medication is applied to ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Relief for Sustained Discomfort

The prolonged-release (LP) formulation may assist with maintaining a more constant level of symptomatic relief, and is commonly used for chronic conditions where persistent symptoms, such as nocturnal pain and pronounced morning stiffness, interfere with daily functional stability.

Regulatory References

1. NIH MedlinePlus overview of Ketoprofen

Official Eligibility and Exclusion

Bi-Profenid LP is an extended-release formulation of ketoprofen, an NSAID. Regulatory authorities define eligibility by specific contraindications and requirements for special caution based on a patient’s health status, allergic history, and physiological state.

Populations That Must Not Use (Contraindicated)

Exclusion Criteria	Constraint Details
Hypersensitivity	Known allergy to ketoprofen or history of asthma, hives, or allergic-type reactions caused by aspirin or other NSAIDs.
Cardiovascular Surgery	For the relief of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Late Pregnancy	Starting at 30 weeks gestation due to risk of fetal harm (premature closure of the ductus arteriosus).
Condition	Active or history of gastrointestinal bleeding or perforation associated with previous NSAID therapy.

Populations Requiring Special Consideration

• Pregnancy (20–30 Weeks): Use should be limited in dose and duration, and monitoring for fetal kidney function should be considered.
• Elderly or Debilitated Patients: Use requires careful assessment, as age-related changes, such as reduced kidney function, may increase risk. Initial dosing of immediate-release formulations may be preferred for safe titration.
• Pediatric Population: Safety and efficacy have not been established; therefore, use is not permitted in children.
• Lactation: Use during breastfeeding is not recommended due to the potential for serious adverse reactions in the infant.

The interaction profile of Ketoprofen is defined by specific regulatory constraints governing co-administration with other substances and medicinal products.

Due to the risk of additive synergistic effects, regulatory documents classify co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and high-dose Salicylates as contraindicated combinations. Similarly, the co-administration of Ketoprofen with Oral Anticoagulants is classified as a combination to be avoided due to the documented increased risk of a hemorrhagic effect. This additive risk extends to Corticosteroids and Selective Serotonin Reuptake Inhibitors (SSRIs), where an increased potential for gastrointestinal ulceration is noted.

Specific pharmacokinetic interactions affect the renal clearance of co-administered medicines. Ketoprofen reduces the clearance of Lithium and high-dose Methotrexate, which can lead to elevated blood concentrations of these drugs. To mitigate this risk, a mandatory 12-hour separation rule applies when administering Ketoprofen relative to Methotrexate treatment.

Furthermore, Ketoprofen's interaction with agents such as Diuretics and ACE Inhibitors/ARBs is documented to potentially reduce their efficacy and increase the risk of renal function impairment. Consumption of Alcohol is noted to increase the risk of gastrointestinal adverse events. For the prolonged-release formulation, a high-fat meal is documented to delay and reduce the peak plasma concentration. Finally, official labeling notes that in the elderly and those with renal impairment, a Ketoprofen metabolite may accumulate, acting as a potential reservoir for the parent drug.

Molecular Mechanism: Inhibiting Prostaglandin Synthesis

Bi-Profenid LP's active ingredient, Ketoprofen, acts primarily by reversibly inhibiting the cyclooxygenase (COX) enzymes, specifically both the COX-1 and COX-2 isoforms. This non-selective inhibition blocks the conversion of arachidonic acid into prostaglandins—key lipid mediators involved in regulating local physiological responses. This action modulates the chemical signals that initiate the inflammatory cascade and contribute to nociceptive sensitization.

---

Physiological Effects on Signaling and Thermoregulation

The resulting reduction in prostaglandins influences multiple physiological systems. By lowering prostaglandin levels at the site of tissue damage, the mechanism reduces the sensitization of peripheral nociceptors (pain receptors), thereby modulating the nociceptive threshold. Furthermore, the central action on the hypothalamus reverses the PGE2-driven signal that sets the body's temperature higher during fever, facilitating the resetting of the hypothalamic thermal set-point.

---

Prolonged Pathway Modulation

The specialized prolonged-release (LP) formulation is designed to ensure sustained target engagement. This dual-release system is a delivery mechanism intended to quickly initiate COX inhibition and then achieve stable maintenance of enzyme inhibition over an extended period. This promotes continuous engagement of the PGE2 signaling pathways over an extended duration.

The administration of Bi-Profenid LP (Ketoprofen prolonged-release) follows specific administration standards. The approved route is oral, with the medication designed to be taken once daily. The standard maintenance dose typically ranges from 100 mg to 200 mg per day, with the maximum extended-release dose generally limited to 200 mg daily for chronic conditions.

To ensure the controlled delivery is maintained, the prolonged-release tablet or capsule must be swallowed whole; cutting, crushing, or chewing the unit is strictly prohibited, as this would compromise the formulation's specialized release profile. The medication can be taken with food, milk, or antacids to enhance tolerability, although food does not alter the total systemic availability of the dose.

A core principle governing the use of all NSAIDs, including this prolonged-release formulation, is the use of the lowest effective dose for the shortest duration necessary. Specific modifications to the standard regimen are applied for certain populations. Older adults and patients with impaired renal or hepatic function require a lower initial dose and maximum dose. For instance, the maximum dose for severe renal impairment is limited to 100 mg per day. Use in adolescents is authorized from 15 years of age. If a dose is missed, the standard procedure is to take it as soon as remembered, unless the next dose is due shortly, in which case the missed dose is skipped entirely.

I. Core Efficacy Research

Research has evaluated Bi-Profenid LP (ketoprofen prolonged release) as an option for managing symptoms in specific painful conditions. Studies primarily focused on participants with acute pain or acute episodes of chronic rheumatic and traumatic conditions. Early clinical trials examined whether administration of the drug was associated with changes in patient-reported pain scores and disease activity assessments.

• Mechanism of Action: Studies evaluated the drug's interaction with specific receptors in the body and assessed outcomes related to patient-reported pain and inflammation scores, consistent with its classification as a non-steroidal anti-inflammatory drug (NSAID).
• Initial Findings: Early trials explored whether changes occurred in quality of life assessments. Findings from these initial studies showed that most participants tolerated the treatment protocol used, with a measurable reduction in pain reported in the majority of assessed cases.

---

II. Long-Term Data and Safety Observations

Long-term studies explored the measured outcomes over periods exceeding one year, examining whether initial measurements were maintained over time.

• Adverse Events: Studies reported the most commonly observed adverse events in the study populations included mild gastrointestinal discomfort and temporary injection site reactions. Rare, serious events consistent with the known class effects of NSAIDs (e.g., cardiovascular and gastrointestinal risks) were also monitored.
• Population Focus: Studies investigated measured outcomes in participants characterized as high-risk, including individuals with certain pre-existing conditions, to monitor the drug's tolerability in these groups.

---

III. Comparative and Combination Research

Research evaluated the use of combination therapy compared to monotherapy. This research examined various drug regimens to understand different treatment approaches and their effects on measured outcomes. Studies often used a protocol that involved starting at a low dose and increasing it based on predefined criteria, and research also examined the effects of different delivery methods on the overall measured outcomes.

Common questions about Bi-Profenid LP (FAQ)

Q: Can Bi-Profenid LP be used for general headache relief?

Official documents list the approved uses of Bi-Profenid LP as symptomatic relief for pain, inflammation, and certain rheumatic disorders. While it is classified for general pain relief, specific regulatory indications may not explicitly name common headaches. The official product labeling describes the specific conditions for which the medicine has been approved.

Q: Is there a recommended limit for how long someone can use Bi-Profenid LP?

Regulatory guidelines for NSAIDs, including this medication, state that it should be used at the lowest effective dose for the shortest duration necessary. This requirement is in place due to the potential risk of serious cardiovascular and gastrointestinal adverse events, which may increase with the length of use.

Q: Are there signs of a serious side effect I should look out for while taking Bi-Profenid LP?

Official regulatory warnings describe specific signs associated with serious adverse reactions. For instance, signs of a serious gastrointestinal event include bloody or black/tarry stools and vomit that resembles coffee grounds. Signs related to cardiovascular events include sudden chest pain, weakness on one side of the body, or shortness of breath.

Q: Is Bi-Profenid LP known to cause dizziness or drowsiness?

Yes, official documents list dizziness as a commonly reported side effect. In addition to dizziness, drowsiness has also been noted among the range of possible side effects that may occur.

Q: What is the guidance regarding alcohol consumption while taking this medication?

According to official product information, consuming alcohol while taking this medicine may increase the risk of gastrointestinal adverse events. This enhanced risk includes potential issues like bleeding or ulceration in the stomach or intestines.

Q: How quickly does the pain relief from Bi-Profenid LP typically begin?

The prolonged-release (LP) formulation is a delivery system designed to provide sustained engagement of the target enzyme over an extended period. While the formulation includes an immediate-release component, regulatory studies indicate that the drug's extended-release plasma concentration begins to rise around two to three hours after administration to achieve its consistent, sustained level.

Q: Can I take Bi-Profenid LP if I have a history of asthma?

Official information states that Bi-Profenid LP is strictly contraindicated for individuals who have a history of aspirin-sensitive asthma. Official labeling notes that patients with non-aspirin-sensitive asthma are considered a special population that may require careful monitoring during use.

Q: Are there any known interactions between Bi-Profenid LP and common supplements?

Regulatory drug interaction lists focus primarily on co-administration with other medicines, not specific common dietary or herbal supplements. Due to the potential for unforeseen effects, official regulatory guidance recommends that individuals inform a healthcare professional about all supplements and herbal products being used.

Q: Does Bi-Profenid LP affect kidney function?

According to official safety information, Bi-Profenid LP can potentially cause a dose-dependent reduction in renal blood flow in some individuals. The medicine is not recommended for patients with advanced renal disease, and those with existing kidney impairment require a lower dose.

Q: What is known about the use of Bi-Profenid LP during pregnancy?

Official warnings advise avoiding this medicine entirely after 20 weeks of gestation due to potential fetal risks. For use before 20 weeks, regulatory guidelines recommend limiting the dose and duration. The decision to use it during this period typically involves a discussion with a healthcare professional about potential benefits and risks.

Q: Can Bi-Profenid LP be taken at the same time as low-dose Aspirin?

The co-administration of this medicine with low-dose Aspirin, often taken for cardiovascular protection, requires extreme caution. This combination is known to increase the risk of serious side effects, particularly gastrointestinal ulcers and bleeding, and often requires careful monitoring.

Q: What should be done if I experience a skin rash while taking Bi-Profenid LP?

Regulatory instructions indicate that if a patient observes skin changes such as blistering, a rash, or swelling, the medicine is to be discontinued. Official guidelines state that these symptoms can be signs of a serious reaction, requiring immediate medical attention.

Q: Can Bi-Profenid LP make you more sensitive to the sun?

Yes, official warnings note that the active ingredient, Ketoprofen, may cause photosensitivity reactions. This means that the skin can become more sensitive to sunlight and ultraviolet (UV) exposure, potentially leading to a rash or sunburn.

Q: Does taking Bi-Profenid LP require regular blood tests?

Routine blood tests are not universally required for all users, but official documents advise careful monitoring for certain patient groups. Monitoring is generally recommended for those taking the medicine alongside specific interacting drugs (like Lithium or high-dose Methotrexate) and for high-risk patients with pre-existing kidney or liver impairment.

Q: Can Bi-Profenid LP be taken with antacids?

Yes, the medicine can be taken with antacids to help improve gastrointestinal tolerability. Official studies indicate that certain antacids, such as aluminum phosphate, do not significantly alter the overall absorption of the drug.

Q: What is the guidance on using Bi-Profenid LP while breastfeeding?

The use of this medicine is generally not recommended while breastfeeding. Official reports cite the potential for serious adverse reactions in the infant, specifically regarding kidney or gastrointestinal function.

Q: Does Bi-Profenid LP have known interactions with common anti-depressants?

Official interaction warnings highlight an increased risk of gastrointestinal bleeding or ulceration when this medication is taken alongside certain types of antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs). Official guidelines recommend that a healthcare professional review the patient's full medication list before use.

Q: What are the signs of a potential liver problem while on Bi-Profenid LP?

Warnings regarding liver problems mention symptoms such as yellowing of the skin or eyes, medically known as jaundice. Other signs include pain in the upper right part of the abdomen, unexplained fatigue, and a general loss of appetite.

Q: Can Bi-Profenid LP be taken with other pain relievers like paracetamol (acetaminophen)?

Official regulatory information has not consistently reported major interactions with Paracetamol (Acetaminophen). Official documents suggest that the use of any combination of pain relievers be reviewed by a healthcare professional.

Q: Why is Bi-Profenid LP not generally recommended after the 20th week of pregnancy?

After 20 weeks of gestation, the medicine is not recommended due to the potential for serious fetal harm. This risk specifically relates to potential problems with the fetal kidneys and the possible premature closure of the ductus arteriosus (a blood vessel in the baby’s heart).

Q: What is the duration of action for a dose of Bi-Profenid LP?

The prolonged-release formulation is a delivery system designed to provide sustained engagement of the target enzyme over an extended period. The aim is to maintain a consistent drug concentration that aligns with the recommended once-daily dosing schedule.

Q: Is it possible for Bi-Profenid LP to cause ringing in the ears?

Yes, ringing in the ears is a potential adverse effect. This symptom, medically known as tinnitus, is listed in official product documents as one of the possible effects of the medicine.

Q: Is Bi-Profenid LP generally taken with food or on an empty stomach?

While this medicine can be taken on an empty stomach, it is generally recommended to take it with food, milk, or a large glass of water. Official regulatory documents describe that taking the medicine with food, milk, or a large glass of water is a common practice associated with improving tolerability.

Q: Is Bi-Profenid LP an opioid or habit-forming drug?

Bi-Profenid LP is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not an opioid, and it is not classified as a habit-forming controlled substance.

Q: Are there any research studies about the effectiveness of Bi-Profenid LP in specific chronic pain conditions?

Clinical research has explored the drug's use for managing symptoms in specific painful conditions. Studies primarily focused on acute pain or acute episodes of chronic conditions, such as rheumatic and traumatic conditions.

How to Store and Dispose of Bi-Profenid LP?

This section describes the official storage and disposal requirements defined by regulatory bodies.

Storage Condition Type	Requirement
Temperature Range	Store at Controlled Room Temperature (20 C to 25 C).
Environmental Protection	Protect the medicine from excessive heat, moisture, and direct light.
Prohibited Environments	Do not freeze the medicine. Avoid damp areas, such as the bathroom.
Packaging Rules	Keep the tablets in the original container and ensure it is tightly closed.
Child-Safety Mandate	Keep this medication out of the sight and reach of children. Always secure safety caps.
Disposal Instructions	Discard outdated or no longer needed medicine. Ask a healthcare professional or pharmacist about local drug take-back programs. Do not dispose of the tablets by flushing them down a toilet or pouring them down a drain.